Patent 10266487 was granted and assigned to FORMA Therapeutics on April, 2019 by the United States Patent and Trademark Office.
The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors.